Chimerix Inc (CMRX)
0.9944
+0.02
(+2.54%)
USD |
NASDAQ |
May 17, 16:00
0.9944
0.00 (0.00%)
After-Hours: 20:00
Chimerix SG&A Expense (Quarterly): 5.546M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 5.546M |
December 31, 2023 | 5.17M |
September 30, 2023 | 9.304M |
June 30, 2023 | 4.448M |
March 31, 2023 | 5.679M |
December 31, 2022 | 5.347M |
September 30, 2022 | 5.313M |
June 30, 2022 | 5.84M |
March 31, 2022 | 5.632M |
December 31, 2021 | 5.241M |
September 30, 2021 | 4.887M |
June 30, 2021 | 4.408M |
March 31, 2021 | 4.136M |
December 31, 2020 | 4.19M |
September 30, 2020 | 3.151M |
June 30, 2020 | 3.11M |
March 31, 2020 | 3.205M |
December 31, 2019 | 3.147M |
September 30, 2019 | 4.024M |
June 30, 2019 | 6.312M |
March 31, 2019 | 7.686M |
December 31, 2018 | 5.007M |
September 30, 2018 | 5.187M |
June 30, 2018 | 6.65M |
March 31, 2018 | 6.738M |
Date | Value |
---|---|
December 31, 2017 | 7.618M |
September 30, 2017 | 6.65M |
June 30, 2017 | 6.284M |
March 31, 2017 | 6.596M |
December 31, 2016 | 5.648M |
September 30, 2016 | 5.827M |
June 30, 2016 | 6.607M |
March 31, 2016 | 6.924M |
December 31, 2015 | 9.484M |
September 30, 2015 | 8.524M |
June 30, 2015 | 7.234M |
March 31, 2015 | 6.123M |
December 31, 2014 | 5.715M |
September 30, 2014 | 4.717M |
June 30, 2014 | 4.423M |
March 31, 2014 | 2.672M |
December 31, 2013 | 2.574M |
September 30, 2013 | 2.029M |
June 30, 2013 | 2.188M |
March 31, 2013 | 1.536M |
December 31, 2012 | 1.441M |
September 30, 2012 | 1.836M |
June 30, 2012 | 1.545M |
March 31, 2012 | 1.926M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
3.11M
Minimum
Jun 2020
9.304M
Maximum
Sep 2023
4.904M
Average
5.028M
Median
SG&A Expense (Quarterly) Benchmarks
UFP Technologies Inc | 13.91M |
Dentsply Sirona Inc | 417.00M |
Arbutus Biopharma Corp | 5.312M |
Pacira BioSciences Inc | 72.03M |
Karyopharm Therapeutics Inc | 29.55M |